{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:03:24Z","timestamp":1785348204652,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.msard.2021.103395","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T11:54:27Z","timestamp":1636545267000},"page":"103395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The effects of HMG-CoA reductase inhibitors on disease activity in multiple sclerosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"58","author":[{"given":"Maria-Ioanna","family":"Stefanou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Palaiodimou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristeidis H.","family":"Katsanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haralampos","family":"Milionis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kosmidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaia","family":"Lambadiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Halvatsiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Ferentinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Andreadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Marinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Theodorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S","family":"Tzartos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Voumvourakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsivgoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Giannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103395_bib0010","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.20021425","article-title":"Treatment of relapsing paralysis in experimental encephalomyelitis by targeting th1 cells through atorvastatin","volume":"197","author":"Aktas","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2021.103395_bib0047","doi-asserted-by":"crossref","first-page":"e29819","DOI":"10.1371\/journal.pone.0029819","article-title":"Multiple sclerosis risk variant hla-drb1\u00d71501 associates with high expression of drb1 gene in different human populations","volume":"7","author":"Alcina","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2021.103395_bib0018","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000319698.40024.1c","article-title":"Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis","volume":"71","author":"Birnbaum","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103395_bib0038","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1161\/01.ATV.0000120374.59826.1b","article-title":"Brain cholesterol: long secret life behind a barrier","volume":"24","author":"Bj\u00f6rkhem","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.msard.2021.103395_bib0032","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(17)30113-8","article-title":"Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the ms-stat randomised, placebo-controlled trial","volume":"16","author":"Chan","year":"2017","journal-title":"The Lancet. Neurol."},{"key":"10.1016\/j.msard.2021.103395_bib0019","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","article-title":"Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (ms-stat): a randomised, placebo-controlled, phase 2 trial","volume":"383","author":"Chataway","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.103395_bib0027","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"2013"},{"key":"10.1016\/j.msard.2021.103395_bib0056","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(11)70105-3","article-title":"Vascular aspects of multiple sclerosis","volume":"10","author":"D'Haeseleer","year":"2011","journal-title":"The Lancet. Neurol."},{"key":"10.1016\/j.msard.2021.103395_bib0002","doi-asserted-by":"crossref","first-page":"Iii39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.msard.2021.103395_bib0028","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.msard.2021.103395_bib0059","article-title":"Statins block interferon signaling in human immune cells: potential loss of the therapeutic effect of ifn beta in multiple sclerosis","volume":"68","author":"Dhawan","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103395_bib0029","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2021.103395_bib0055","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(11)70124-7","article-title":"The multiple sclerosis mystery: is there a vascular component?","volume":"10","author":"Filippi","year":"2011","journal-title":"The Lancet. Neurol."},{"key":"10.1016\/j.msard.2021.103395_bib0037","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/brain\/awh417","article-title":"Inflammation stimulates remyelination in areas of chronic demyelination","volume":"128","author":"Foote","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103395_bib0044","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awl083","article-title":"The value of animal models for drug development in multiple sclerosis","volume":"129","author":"Friese","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103395_bib0035","first-page":"16","article-title":"Interferon \u03b2-1a and atorvastatin in the treatment of multiple sclerosis","volume":"13","author":"Ghasami","year":"2016","journal-title":"Iran J. Immunol."},{"key":"10.1016\/j.msard.2021.103395_bib0026","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2021.103395_bib0052","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12883-019-1366-7","article-title":"Multiple sclerosis and stroke: a systematic review and meta-analysis","volume":"19","author":"Hong","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2021.103395_bib0006","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1471-4159.2006.04375.x","article-title":"Simvastatin protects neurons from cytotoxicity by up-regulating bcl-2 mrna and protein","volume":"101","author":"Johnson-Anuna","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.msard.2021.103395_bib0050","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3899\/jrheum.171389","article-title":"The effect of statin use on mortality in systemic autoimmune rheumatic diseases","volume":"45","author":"Jorge","year":"2018","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.msard.2021.103395_bib0003","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1191\/0961203303lu2135oa","article-title":"Statins: immunomodulators for autoimmune rheumatic disease?","volume":"14","author":"Jury","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.msard.2021.103395_bib0020","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00415-012-6513-7","article-title":"Atorvastatin added to interferon \u03b2 for relapsing multiple sclerosis: a randomized controlled trial","volume":"259","author":"Kamm","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103395_bib0016","doi-asserted-by":"crossref","first-page":"e86663","DOI":"10.1371\/journal.pone.0086663","article-title":"Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter swabims trial","volume":"9","author":"Kamm","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2021.103395_bib0053","first-page":"181","article-title":"Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis","volume":"87","author":"Kappus","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.msard.2021.103395_bib0049","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.therap.2016.09.017","article-title":"Pharmacogenetics in cardiovascular diseases: state of the art and implementation-recommendations of the french national network of pharmacogenetics (rnpgx)","volume":"72","author":"Lamoureux","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.msard.2021.103395_bib0015","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/1352458509358909","article-title":"Atorvastatin combined to interferon to verify the efficacy (active) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy","volume":"16","author":"Lanzillo","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103395_bib0021","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1177\/1352458515611222","article-title":"No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon \u03b21b therapy in relapsing-remitting multiple sclerosis (the arianna study)","volume":"22","author":"Lanzillo","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103395_bib0042","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.msard.2018.12.042","article-title":"Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin","volume":"28","author":"Lanzillo","year":"2019","journal-title":"Mult Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103395_bib0005","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis","volume":"9","author":"Lassmann","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2021.103395_bib0048","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.msard.2021.103395_bib0024","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103395_bib0043","doi-asserted-by":"crossref","first-page":"20607","DOI":"10.3390\/ijms151120607","article-title":"Molecular mechanisms underlying the effects of statins in the central nervous system","volume":"15","author":"McFarland","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2021.103395_bib0007","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/glia.20441","article-title":"Simvastatin regulates oligodendroglial process dynamics and survival","volume":"55","author":"Miron","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.msard.2021.103395_bib0040","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.2353\/ajpath.2009.080947","article-title":"Statin therapy inhibits remyelination in the central nervous system","volume":"174","author":"Miron","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.msard.2021.103395_bib0057","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/ene.12720","article-title":"The framingham cardiovascular risk score in multiple sclerosis","volume":"22","author":"Moccia","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.103395_bib0004","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the american heart association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.msard.2021.103395_bib0022","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the prisma 2020 statement","volume":"134","author":"Page","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2021.103395_bib0054","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/jamaneurol.2020.0664","article-title":"Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in england","volume":"77","author":"Palladino","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103395_bib0013","doi-asserted-by":"crossref","first-page":"e1928","DOI":"10.1371\/journal.pone.0001928","article-title":"Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis","volume":"3","author":"Paul","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2021.103395_bib0036","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1352458511421920","article-title":"Statin therapy and multiple sclerosis disability in a population-based cohort","volume":"18","author":"Paz Sold\u00e1n","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103395_bib0041","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40263-015-0239-x","article-title":"Statin treatment in multiple sclerosis: a systematic review and meta-analysis","volume":"29","author":"Pihl-Jensen","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2021.103395_bib0025","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the mcdonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103395_bib0023","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103395_bib0039","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nn1426","article-title":"High cholesterol level is essential for myelin membrane growth","volume":"8","author":"Saher","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.msard.2021.103395_bib0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2021.103395_bib0011","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s00415-003-1070-8","article-title":"Therapeutic potential of lovastatin in multiple sclerosis","volume":"250","author":"Sena","year":"2003","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103395_bib0058","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/25785826.2018.1531190","article-title":"Blood-brain barrier dysfunction in immuno-mediated neurological diseases","volume":"41","author":"Shimizu","year":"2018","journal-title":"Immunol. Med."},{"key":"10.1016\/j.msard.2021.103395_bib0017","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S1474-4422(11)70144-2","article-title":"Simvastatin as add-on therapy to interferon \u03b2-1a for relapsing-remitting multiple sclerosis (simcombin study): a placebo-controlled randomised phase 4 trial","volume":"10","author":"Sorensen","year":"2011","journal-title":"The Lancet. Neurology."},{"key":"10.1016\/j.msard.2021.103395_bib0008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3940(99)00414-0","article-title":"Amelioration of experimental allergic encephalomyelitis in lewis rats by lovastatin","volume":"269","author":"Stanislaus","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.msard.2021.103395_bib0051","doi-asserted-by":"crossref","unstructured":"Tascilar K., Dell'Aniello S., Hudson M., Suissa S. Statins and risk of rheumatoid arthritis: a nested case-control study. 2016;68:2603\u20132611.","DOI":"10.1002\/art.39774"},{"key":"10.1016\/j.msard.2021.103395_bib0030","unstructured":"Team R.C. R: a language and environment for statistical com-puting. 2017."},{"key":"10.1016\/j.msard.2021.103395_bib0046","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1186\/s12864-020-06966-4","article-title":"Genetic variants modulate gene expression statin response in human lymphoblastoid cell lines","volume":"21","author":"Theusch","year":"2020","journal-title":"BMC Genomics"},{"key":"10.1016\/j.msard.2021.103395_bib0014","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/1352458510369147","article-title":"Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial","volume":"16","author":"Togha","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103395_bib0034","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458511415452","article-title":"Simvastatin improves final visual outcome in acute optic neuritis: a randomized study","volume":"18","author":"Tsakiri","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103395_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in r with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.msard.2021.103395_bib0012","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(04)16205-3","article-title":"Oral simvastatin treatment in relapsing-remitting multiple sclerosis","volume":"363","author":"Vollmer","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.103395_bib0033","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1212\/WNL.0b013e31824f7fdd","article-title":"Randomized controlled trial of atorvastatin in clinically isolated syndrome: the staycis study","volume":"78","author":"Waubant","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103395_bib0001","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/archneurol.2010.199","article-title":"3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in the treatment of central nervous system diseases","volume":"67","author":"Willey","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2021.103395_bib0009","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature01158","article-title":"The hmg-coa reductase inhibitor, atorvastatin, promotes a th2 bias and reverses paralysis in central nervous system autoimmune disease","volume":"420","author":"Youssef","year":"2002","journal-title":"Nature"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:03:48Z","timestamp":1761901428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821006623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":59,"alternative-id":["S2211034821006623"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103395","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of HMG-CoA reductase inhibitors on disease activity in multiple sclerosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103395"}}